AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23468128
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg/day to 600 mg/day) followed by cabergoline (0.5‐1 mg/week up to 3.0 mg/week)
Trial: 18930473
Drug: Serial sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial sleep deprivation therapy (six nights of total SD within three weeks, separated by nights of recovery sleep)
Trial: 18930473
Drug: No sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sleep deprivation therapy (control group)
Trial: 17086382
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) therapy, 25 min per session, 5 days per week for 3 weeks.
Trial: 17086382
Drug: Sham PEMF
RxNorm normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham PEMF therapy, 25 min per session, 5 days per week for 3 weeks.
Trial: 11593723
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg.kg‐1, orally, administered 45 min before induction) in Group M
Trial: 2968548
Drug: Clomiphene citrate-human
RxNorm normalized name: Clomiphene Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate-human menopausal gonadotropin combination without LH-RH analogue (control group)
Trial: 31545115
Drug: Parent-focused stress
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-focused stress management intervention (four individual sessions with a community wellness coach over 3 months, supplemented with weekly text messaging and twice monthly group sessions for 6 months)
Trial: 30722059
Drug: Lefamulin 150
RxNorm normalized name: lefamulin 150 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lefamulin 150 mg IV every 12 hours
Trial: 30722059
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg IV every 24 hours
Trial: 19746673
Drug: Solubilized 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solubilized 5% BPO gel
Trial: 11095452
Drug: sc insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sc insulin (INS)
Trial: 8341987
Drug: Omeprazole and
RxNorm normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole and amoxycillin combination therapy (n = 30)
Trial: 8341987
Drug: Omeprazole monotherapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole monotherapy (n = 30)
Trial: 3088652
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg at 8 a.m.
Trial: 3088652
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg at 11 p.m.
Trial: 3088652
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg at 2 a.m.
Trial: 3088652
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg at 5 a.m.
Trial: 29488152
Drug: DS-8500a 50
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a 50 mg
Trial: 26934259
Drug: Insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/liraglutide (n=278; maximum dose, 50 U of degludec/1.8 mg of liraglutide)
Trial: 26934259
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (n=279; no maximum dose)
Trial: 26934259
Drug: Insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/liraglutide
Trial: 23509088
Drug: Low coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low coffee consumption (< 200 ml/day)
Trial: 23509088
Drug: Moderate coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate coffee consumption (200‐450 ml/day)
Trial: 23509088
Drug: High coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High coffee consumption (> 450 ml/day)
Trial: 18768350
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg (antihypertensive dose)
Trial: 12756157
Drug: Nurse facilitator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse facilitator (supervised nurse to initiate and titrate beta-blockers)
Trial: 12756157
Drug: Provider and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider and patient notification (computerized provider reminders and patient letters advocating beta-blockers)
Trial: 9196608
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (OD) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Trial: 9196608
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Trial: 8198761
Drug: Controlled-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulation (Orfil retard enteric coated tablet)
Trial: 8198761
Drug: Plain tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain tablet (reference drug)
Trial: 3798537
Drug: Russell's viper
RxNorm normalized name: Russell's viper venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Russell's viper venoid (0.5 ml subcutaneous injection followed by two booster injections at four-week intervals)
Trial: 23197780
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) with insulin
Trial: 23197780
Drug: Akt inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Akt inhibitor (wortmannin)
Trial: 8145004
Drug: Hemofer (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemofer (2 tablets = 18 mg iron/day)
Trial: 8145004
Drug: Erco-Fer (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erco-Fer (1 tablet = 60 mg iron/day)
Trial: 1948094
Drug: Defibrotide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 400 mg b.i.d. for 6 months
Trial: 1948094
Drug: Defibrotide 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 800 mg o.d. for 6 months
Trial: 1948094
Drug: Defibrotide 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 800 mg
Trial: 29653
Drug: Trimepranol (10-14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimepranol (10-14 mg/twice daily)
Trial: 29653
Drug: Chlorthalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (50 mg every second day)
Trial: 29653
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trimepranol and chlorthalidone
Trial: 26335089
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives of £15 (US $23) for each long-acting injectable antipsychotic (LAI) received.
Trial: 7880938
Drug: Arginine (ARG)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine (ARG) 30 g infused over 30 min starting at 0 min
Trial: 7880938
Drug: Pyridostigmine (PD)
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD) 120 mg orally, 60 min before GHRH administration
Trial: 19512981
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg daily
Trial: 16943402
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (Control)
Trial: 11214707
Drug: DDD pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDD pacing or oral theophylline
Trial: 9598259
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (25 ml.kg-1)
Trial: 9598259
Drug: Dextran 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 3% (10 ml.kg-1)
Trial: 3170960
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (0.27 mmol/kg body weight)
Trial: 31570296
Drug: Dichlorphenamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichlorphenamide (50 mg or 100 mg daily for adolescents)
Trial: 31570296
Drug: Dichlorphenamide (105.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichlorphenamide (105.7 mg mean daily for adults)
Trial: 25494864
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity allele score (GS‐InSens)
Trial: 25494864
Drug: Insulin secretion
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin secretion allele score (GS‐InSec)
Trial: 23243248
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control diet (0.304 g of monocalcium phosphate per kg)
Trial: 21884956
Drug: Ingesting ≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingesting ≥1 of prescribed hypertension medications at bedtime
Trial: 15311218
Drug: Chitosan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan (3 g/day)
Trial: 9369265
Drug: SR 49059
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 49059 (30 mg)
Trial: 2417834
Drug: 5% plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% plasma protein solution
Trial: 27178047
Drug: fasiglifam 25
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasiglifam 25 mg once daily
Trial: 27178047
Drug: fasiglifam 50
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasiglifam 50 mg once daily
Trial: 27178047
Drug: fasiglifam monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasiglifam monotherapy
Trial: 27178047
Drug: sulphonylurea combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphonylurea combination therapy
Trial: 27178047
Drug: fasiglifam (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fasiglifam (both doses)
Trial: 24731434
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS (high dose left prefrontal repetitive transcranial magnetic stimulation)
Trial: 23005919
Drug: Albuterol MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDI with valved spacer
Trial: 23005919
Drug: Albuterol MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDI with non-valved spacer
Trial: 20473771
Drug: Trigeminal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigeminal block with 0.8‐mL lidocaine 2%
Trial: 20473771
Drug: Deep sedation
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation and trigeminal injection of 0.8‐mL saline (Control)
Trial: 10411034
Drug: Sequential BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential BCG and epirubicin (group 1)
Trial: 1883257
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d) for 2 weeks
Trial: 1883257
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at neuroleptic threshold dosages (mean, 3.4 +/- 2.3 mg/d) for 2 weeks
Trial: 1883257
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d)
Trial: 6870221
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of metronidazole (500 mg over 20 min)
Trial: 6870221
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of tinidazole (500 mg over 20 min)
Trial: 6870221
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of metronidazole (500 mg)
Trial: 6870221
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tinidazole (500 mg)
Trial: 6870221
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of metronidazole (1,000 mg)
Trial: 6870221
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of tinidazole (1,000 mg)
Trial: 6870221
Drug: Intravaginal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal administration of metronidazole (500 mg)
Trial: 6870221
Drug: Intravaginal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal administration of tinidazole (500 mg)
Trial: 6870221
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of either drug
Trial: 6870221
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of either drug
Trial: 6870221
Drug: Intravaginal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal administration of either drug
Trial: 29894202
Drug: Insulin intervention
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin intervention during dual clamp in MHD patients
Trial: 29894202
Drug: Insulin intervention
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin intervention during dual clamp in controls
Trial: 20078686
Drug: C-HAT (currently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-HAT (currently on heroin-assisted treatment)
Trial: 15845709
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine plus IV morphine via patient‐controlled analgesia (ITM+PCA group)
Trial: 15845709
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine via patient‐controlled analgesia (PCA‐only group)
Trial: 10354965
Drug: Pleconaril oral
RxNorm normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleconaril oral capsules (50 to 1000 mg)
Trial: 8550116
Drug: Atenolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50-100 mg per day)
Trial: 8550116
Drug: Nifedipine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10-20 mg per day)
Trial: 1769321
Drug: L-sulpiride 25
RxNorm normalized name: (±)-sulpiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-sulpiride 25 mg t.i.v./day, p.o. for 30 days
Trial: 6175830
Drug: Prazosin 2
RxNorm normalized name: prazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 2 mg
Trial: 6175830
Drug: Trimazosin 200
RxNorm normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin 200 mg
Trial: 6175830
Drug: UK-33,274 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-33,274 4 mg
Trial: 31091866
Drug: Formulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation of metabolites from both bacterial strains
Trial: 25234481
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment group (control)
Trial: 23968815
Drug: METH (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METH (30 mg)
Trial: 23968815
Drug: METH (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METH (0 mg)
Trial: 19689661
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg loading dose of clopidogrel followed by 150 mg daily for 1 week prior to angiography
Trial: 19689661
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg loading dose of clopidogrel
Trial: 17804841
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (40,000 U weekly for a maximum of 3 weeks)
Trial: 15028824
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (fluorouracil)
Trial: 15028824
Drug: Both chemoradiotherapy
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both chemoradiotherapy and chemotherapy
Trial: 9833860
Drug: Zidovudine, didanosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, didanosine, and nevirapine combination therapy
Trial: 9833860
Drug: More sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More sensitive assay with a lower quantification limit of 20 copies/ml
Trial: 2145232
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg bolus + 2.5 micrograms/kg/minute infusion
Trial: 2145232
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg bolus + 5.0 micrograms/kg/minute infusion
Trial: 2145232
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg bolus + 10.0 micrograms/kg/minute infusion
Trial: 2145232
Drug: Enoximone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 5.0 micrograms/kg/minute infusion without bolus
Trial: 2145232
Drug: Enoximone infusion
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone infusion at rates greater than 5.0 micrograms/kg/minute
Trial: 2145232
Drug: Enoximone infusion
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone infusion
Trial: 6994778
Drug: Guanfacine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (2 to 6 mg daily)
Trial: 6994778
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 to 0.9 mg daily)
Trial: 28086164
Drug: Adjunctive lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive lacosamide
Trial: 28686778
Drug: 2% SA
RxNorm normalized name: Care Touch Alcohol 62% Sanitizing Hand Wipes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% SA topical gel enriched with botanicals
Trial: 25490610
Drug: 7-day buprenorphine
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day buprenorphine tapering schedule
Trial: 25490610
Drug: 28-day buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28-day buprenorphine tapering schedule
Trial: 23719234
Drug: Colistin sulphate
RxNorm normalized name: Colistin sulphate
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin sulphate (50 mg 4×/day) and neomycin sulphate (250 mg 4×/day) for 10 days plus nitrofurantoin (100 mg 3×/day) for 5 days
Trial: 23719234
Drug: Colistin and
RxNorm normalized name: Colistin and hydrocortisone and neomycin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin and neomycin treatment
Trial: 17719313
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 20 mg, TID for 6 months
Trial: 17719313
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual drug therapy) for 6 months
Trial: 9726717
Drug: Beclomethasone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone (mean daily dose, 640 microg)
Trial: 2721103
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of disulfiram daily